Portal de Periódicos da CAPES

Carboplatin, Epirubicin, and VP-16 Chemotherapy in the Treatment of Small Cell Lung Cancer

1994; Lippincott Williams & Wilkins; Volume: 17; Issue: 2 Linguagem: Inglês

10.1097/00000421-199404000-00014

1537-453X

Cesare Gridelli, Giovanni Pietro Ianniello, Alfonso Maiorino, Carlo Curcio, Modesto DʼAprile, L Brancaccio, S. Palmeri, Maria Teresa Gentile, Giuseppe Cornelia, Tonino Pedicini, Giuseppe Airoma, Enzo Veltri, Vittorio Gebbia, Anna Russo, Rossana Casaretti, F Giampaglia, G Ferrante, L Rausa, Stefano Iacobelli, Giorgio Arcangeli, Sabino De Placido, Antonio Bianco,

Cancer therapeutics and mechanisms

In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent "split-course" chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.